An underground economy for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.
Experimental Drug Gaining Traction Online
The experimental drug, which is still in research studies, is being promoted by social media influencers for its alleged fat-burning effects. Viewers are urged to contact these accounts privately for supplier links, while also receiving discount codes.
Thriving Commerce on Messaging Platforms
Additionally, a robust trade exists on messaging services, where communities with numerous of members share “before and after” images, administration instructions and assertions of next-day UK delivery. Sellers market the substance there before directing customers to WhatsApp for transactions.
Understanding The Experimental Drug
This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.
Medical Professionals Express Worries
Nevertheless, physicians and chemists have cautions that the sale of what remains an unlicensed drug in the United Kingdom is a cause for concern and could lead to users administering substances of unknown origin.
Some experts stated the popularity for the experimental drug could be linked to the rising cost of approved weight loss products such as Mounjaro.
Regulatory Position and Enforcement
Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unapproved drug that must not be promoted or distributed for personal consumption under the British medical regulations.
Several influencers try to sidestep the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still violate medicines, advertising, and consumer regulations, potentially leading to fines, legal action or imprisonment.
Platform Reaction and Content Removal
Based on the social media company, the service has taken down violative content and prohibited associated hashtags and query recommendations. The company said it was committed to keeping the service secure and allocating resources in strengthening enforcement strategies.
Online Trading Activities
Research also discovered communities with up to 9,000 participants marketing retatrutide using the platform's integrated search feature, which operates like a online catalog. Typing “retatrutide” immediately brings up groups with numerous of users, populated with images of weight loss, positive testimonials and detailed guides for preparing or administering at residence.
Within moments of joining one group, a vendor shared WhatsApp details, where most transactions take place. The seller sent an instruction manual and guaranteed shipping within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None inquired about body mass, medical conditions or past usage.
Item Details and Pricing
Inside these communities, posts display dark colored parcels with Royal Mail labels, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, prepared at home with purified liquid, or ready-to-use pens usually sold at 160 pounds for 20 milligrams. When questioned how much time a injector should last, sellers give conflicting answers varying between a several days to “depends on your body”.
Service Oversight and Security Actions
A representative for the messaging service said it actively moderated harmful material on its platform including content that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are administering substances they cannot confirm. Even if the research behind this drug is sound, these online versions may not contain what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor linked the surge in interest to current price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to social media. But counterfeit treatments are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she said.
Her team has previously seen patients injured by personal administration from unverified suppliers. “We understand the disappointment, but buying from Telegram or WhatsApp is gambling with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”
Producer Statement
A representative from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, noting that any product “misleadingly claiming itself as a company investigational substance not yet authorized … may expose users to potentially significant medical dangers”.
